ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR-ABL activates downstream signaling pathways to cause CML cell proliferation disorder in patients.143 At present, three generations of BCR-ABL inhibitors have been approved for the clinical treatment of CML.